Risk of Bias Analysis of Systematic Reviews of Probiotics for Treatment of Irritable Bowel Syndrome

Clin Gastroenterol Hepatol. 2019 Mar;17(4):784-785. doi: 10.1016/j.cgh.2018.07.010. Epub 2018 Aug 8.


Global prevalence of irritable bowel syndrome (IBS) is between 7% and 21%.1 Pathogenesis of IBS symptoms such as pain, altered bowel habits, and bloating is multifactorial, with central and peripheral mechanisms serving as targets for treatments.2 Probiotics have been studied for the treatment of IBS and are well tolerated and safe.3.

MeSH terms

  • Adult
  • Humans
  • Irritable Bowel Syndrome / therapy*
  • Probiotics / administration & dosage*
  • Publication Bias / statistics & numerical data*
  • Risk Assessment
  • Systematic Reviews as Topic*
  • Treatment Outcome